Sipilä, Jussi O. T. http://orcid.org/0000-0003-0183-9054
Soilu-Hänninen, Merja
Rautava, Päivi
Kytö, Ville
Funding for this research was provided by:
governmental VTR-funding of the hospital district of Southwestern Finland
Finnish Cardiac Society
Article History
Received: 13 November 2018
Revised: 18 December 2018
Accepted: 21 December 2018
First Online: 5 January 2019
Compliance with ethical standards
:
: Jussi O. T. Sipilä: has received travel grants and congress fee covering (Orion Corporation, Abbvie, Lundbeck, Merck Serono, Sanquin) and holds shares (Orion Corporation). Merja Soilu-Hänninen: has received congress fee covering, investigator fees and honoraria for lectures or advisory boards (Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva). Päivi Rautava: has received congress fee covering (Roche, The Finnish Innovation Fund Sitra). Ville Kytö: none.
: The study was approved by the Turku University Hospital Clinical Research Center (Turku CRC), THL (permissions no.: THL/143/5.05.00/2015 and THL/1349/5.05.00/2015) and Statistics Finland (TK53-1410-15). Ethics committee appraisal was not stipulated since the study did not include any actual contact with patients.